ATL1 (Atlastin-1) variants and mutations
ATL1 (also known as Atlastin-1) is a human protein-coding gene encoding an atlastin-1 protein. It promotes homotypic fusion of endoplasmic-reticulum membranes and is required for normal organization of the tubular ER network, especially in long axons. Dominant pathogenic variants are a common cause of hereditary spastic paraplegia type 3A. This analysis covers 761 ATL1 variants and mutations. Of these, 76% have computational variant effect predictions. Disease context includes hereditary spastic paraplegia 3A, Autosomal dominant spastic paraplegia type 3, and hereditary sensory and autonomic neuropathy type 1. Example ATL1 variants include A2T, A2V, and A2A.
Variant analysis overview
- Gene: ATL1
- Protein: Atlastin-1
- UniProt accession: Q8WXF7
- Organism: Homo sapiens
- Variants analyzed: 761
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 586 unspecified-consequence records; 73 missense variants; 74 synonymous variants; 9 frameshift variants; 8 stop-gained variants; 3 in-frame deletions; 2 splice-region variants; 5 substitution
- Prediction scores: 575 variants have prediction scores (76% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: hereditary spastic paraplegia 3A, Autosomal dominant spastic paraplegia type 3, hereditary sensory and autonomic neuropathy type 1, hereditary spastic paraplegia, hereditary disease, Spastic paraplegia, hereditary sensory and autonomic neuropathy, Dupuytren Contracture, Osteomyelitis leading to amputation due to slow healing fractures, Penetrating foot ulcers, Distal sensory impairment, Distal lower limb muscle weakness.
Protein structure and variant hotspots
- Protein features: 2 transmembrane segments; 1 domains; 21 binding sites; 4 post-translational modification sites.
- Structural context: 378 variants have structural context.
- PTM context: 2 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable ATL1 variants
Examples include A2T, A2V, A2A, K3E, K3Q, N4S, N4D, R5C. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- A2T (p.Ala2Thr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- A2V (p.Ala2Val), gnomAD 14-50560270-C-T, REVEL 0.25, CADD 22.90
- A2A (p.Ala2Ala), gnomAD 14-50560271-C-T, CADD 15.00
- K3E (p.Lys3Glu), gnomAD rs1196523574, REVEL 0.19, CADD 22.70
- K3Q (p.Lys3Gln), gnomAD 14-50560272-A-C, REVEL 0.11, CADD 22.30
- N4S (p.Asn4Ser), TOPMed rs1237400359, gnomAD rs1237400359, REVEL 0.07, CADD 16.70, Uncertain significance, Hereditary spastic paraplegia 3A
- N4D (p.Asn4Asp), gnomAD 14-50560275-A-G, REVEL 0.06, CADD 22.60
- R5C (p.Arg5Cys), NCI-TCGA Cosmic COSV6329, cosmic curated COSV63296, Variant assessed as somatic; moderate impact.
- R5P (p.Arg5Pro), TOPMed rs2038819819
- R5S (p.Arg5Ser), gnomAD 14-50560278-C-A, REVEL 0.23, CADD 24.40
- R5L (p.Arg5Leu), gnomAD 14-50560279-G-T, REVEL 0.36, CADD 24.60
- R5H (p.Arg5His), gnomAD 14-50560279-G-A, REVEL 0.20, CADD 24.70
- R6K (p.Arg6Lys), gnomAD rs1488692032, REVEL 0.05, CADD 20.50
- R6R (p.Arg6Arg), rs2038819928, gnomAD 14-50560283-G-A, CADD 14.70
- D7G (p.Asp7Gly), cosmic curated COSV63296, ExAC rs759476841, gnomAD rs759476841, REVEL 0.28, CADD 31.00
- D7N (p.Asp7Asn), rs2038819987, ClinGen CA389659765, ClinVar RCV001773983, TOPMed rs2038819987, AlphaMissense 0.13, MetaLR 0.44, Uncertain significance, not provided
- R8I (p.Arg8Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- N9K (p.Asn9Lys), rs752593199, ClinGen CA7180146, ClinVar RCV000647933, ClinVar RCV002440339, REVEL 0.08, CADD 22.10, Conflicting interpretations, not provided; Inborn genetic diseases; Hereditary spastic paraplegia 3A
- N9S (p.Asn9Ser), rs767429611, ClinGen CA7180145, ClinVar RCV003821896, ExAC rs767429611, REVEL 0.12, CADD 22.80, Uncertain significance, Hereditary spastic paraplegia 3A
- N9N (p.Asn9Asn), gnomAD 14-50560292-C-T, CADD 14.70
- S10S (p.Ser10Ser), rs146613929, gnomAD 14-50560295-T-C, CADD 13.70
- W11* (p.Trp11Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- W11C (p.Trp11Cys), rs765421231, ClinGen CA7180148, ClinVar RCV001935822, ClinVar RCV002458798, REVEL 0.30, CADD 32.00, Uncertain significance, Inborn genetic diseases; Hereditary spastic paraplegia 3A
- G12D (p.Gly12Asp), rs745354380, ClinGen CA7180162, ClinVar RCV002587623, ExAC rs745354380, REVEL 0.24, CADD 26.70, Uncertain significance, Hereditary spastic paraplegia 3A
- G12R (p.Gly12Arg), ExAC rs750638321, gnomAD rs750638321, REVEL 0.25, CADD 29.60
- G12S (p.Gly12Ser), gnomAD 14-50560299-G-A, REVEL 0.10, CADD 25.10
- G13A (p.Gly13Ala), rs2140201659, ClinGen CA389665135, ClinVar RCV001935161, Ensembl rs2140201659, AlphaMissense 0.07, MetaLR 0.27, Uncertain significance, Hereditary spastic paraplegia 3A
- G13E (p.Gly13Glu), rs2140201659, ClinGen CA389665134, cosmic curated COSV63296, ClinVar RCV003238611, AlphaMissense 0.07, MetaLR 0.27, Uncertain significance, not provided
- G13R (p.Gly13Arg), rs1566722874, Ensembl rs1566722874, REVEL 0.18, CADD 24.00, Variant assessed as somatic; moderate impact.
- G13G (p.Gly13Gly), gnomAD 14-50587835-A-C, CADD 9.08
- F14L (p.Phe14Leu), gnomAD rs1287543679, REVEL 0.21, CADD 22.00
- S15L (p.Ser15Leu), rs772206990, ClinGen CA7180163, NCI-TCGA Cosmic COSV6329, cosmic curated COSV63296, REVEL 0.08, CADD 22.50, Conflicting interpretations, Inborn genetic diseases; Hereditary spastic paraplegia 3A
- S15S (p.Ser15Ser), rs775540772, gnomAD 14-50587841-G-A, CADD 8.92
- E16D (p.Glu16Asp), rs2504484156, ClinGen CA389665156, ClinVar RCV003503977, Uncertain significance, Hereditary spastic paraplegia 3A
- E16Q (p.Glu16Gln), rs1223717112, ClinGen CA389665151, ClinVar RCV000647930, ClinVar RCV005231229, REVEL 0.12, CADD 22.90, Uncertain significance, not provided; Hereditary spastic paraplegia 3A
- E16G (p.Glu16Gly), gnomAD 14-50587843-A-G, REVEL 0.24, CADD 23.50
- T18N (p.Thr18Asn), gnomAD 14-50587848-AC-A, CADD 24.70
- T18I (p.Thr18Ile), gnomAD 14-50587849-C-T, REVEL 0.03, CADD 17.60
- T18T (p.Thr18Thr), gnomAD 14-50587850-A-T, CADD 9.66
- Y19N (p.Tyr19Asn), rs2504484194, ClinGen CA389665172, ClinVar RCV002829483, Uncertain significance, Hereditary spastic paraplegia 3A
- Y19C (p.Tyr19Cys), gnomAD 14-50587852-A-G, REVEL 0.16, CADD 21.50
- Y19Y (p.Tyr19Tyr), gnomAD 14-50587853-T-C, CADD 7.46
- E20K (p.Glu20Lys), rs763902321, NCI-TCGA Cosmic COSV1006, cosmic curated COSV10061, ExAC rs763902321, REVEL 0.18, CADD 23.60, Variant assessed as somatic; moderate impact.
- E20E (p.Glu20Glu), rs2039117245, gnomAD 14-50587856-A-G, CADD 9.74
- W21G (p.Trp21Gly), Ensembl rs1566722905, REVEL 0.36, AlphaMissense 0.76, Uncertain significance
- W21R (p.Trp21Arg), rs1566722905, ClinGen CA389665192, ClinVar RCV001211767, Ensembl rs1566722905, AlphaMissense 0.76, MetaLR 0.44, Uncertain significance, Hereditary spastic paraplegia 3A
- W21* (p.Trp21Ter), gnomAD 14-50587859-G-A, CADD 37.00
- S23L (p.Ser23Leu), ExAC rs773339310, gnomAD rs773339310
- E24Q (p.Glu24Gln), rs763169900, ClinGen CA7180168, ClinVar RCV003079042, ClinVar RCV003079043, REVEL 0.28, CADD 24.50, Conflicting interpretations, Hereditary spastic paraplegia 3A; Inborn genetic diseases
- E24A (p.Glu24Ala), gnomAD 14-50587867-A-C, REVEL 0.31, CADD 27.30
- E24E (p.Glu24Glu), gnomAD 14-50587868-A-G, CADD 11.70
- E25D (p.Glu25Asp), rs766461592, ExAC rs766461592, gnomAD rs766461592, ClinGen CA7180169, REVEL 0.28, CADD 17.30, Uncertain significance, Inborn genetic diseases
- E25V (p.Glu25Val), gnomAD rs1237660018
- E25E (p.Glu25Glu), rs766461592, gnomAD 14-50587871-G-A, CADD 8.90
- E26E (p.Glu26Glu), gnomAD 14-50587874-G-A, CADD 6.58
- E27K (p.Glu27Lys), cosmic curated COSV10467, Ensembl rs955468184
- E27del (p.Glu27del), gnomAD 14-50587868-AGAG-, CADD 21.10
- E27* (p.Glu27Ter), gnomAD 14-50587875-G-T, CADD 38.00
- E27D (p.Glu27Asp), gnomAD 14-50587877-G-C, REVEL 0.14, CADD 15.40
- P28S (p.Pro28Ser), gnomAD 14-50587877-GCC-G, CADD 25.70
- P28L (p.Pro28Leu), gnomAD 14-50587879-C-T, REVEL 0.09, CADD 22.30
- P28P (p.Pro28Pro), rs35014209, gnomAD 14-50587880-A-G, CADD 9.47
- V29A (p.Val29Ala), rs2140201745, ClinGen CA389665298, ClinVar RCV001986234, Ensembl rs2140201745, REVEL 0.09, CADD 19.40, Uncertain significance, Hereditary spastic paraplegia 3A
- V29L (p.Val29Leu), ExAC rs755019483, gnomAD rs755019483, REVEL 0.10, CADD 18.20
- V29R (p.Val29Arg), gnomAD 14-50587880-A-AAG, CADD 27.90
- V29V (p.Val29Val), rs142314314, gnomAD 14-50587883-G-A, CADD 10.90
- K30K (p.Lys30Lys), rs200452381, gnomAD 14-50587886-A-G, CADD 9.74
- K31R (p.Lys31Arg), gnomAD 14-50587883-GA-G, CADD 27.00
- K31K (p.Lys31Lys), gnomAD 14-50587889-G-A, CADD 9.93
- G33A (p.Gly33Ala), ExAC rs753197391, gnomAD rs753197391, REVEL 0.12, CADD 20.80
- P34P (p.Pro34Pro), gnomAD 14-50587898-A-T, CADD 8.20
- V35L (p.Val35Leu), gnomAD 14-50587899-G-C, REVEL 0.19, CADD 22.00
- V35I (p.Val35Ile), gnomAD 14-50587899-G-A, REVEL 0.11, CADD 21.10
- V35F (p.Val35Phe), gnomAD 14-50587899-G-T, REVEL 0.31, CADD 25.60
- Q36E (p.Gln36Glu), gnomAD 14-50587902-C-G, REVEL 0.38, CADD 22.90
- V37I (p.Val37Ile), gnomAD 14-50587905-G-A, REVEL 0.10, CADD 17.90
- V37V (p.Val37Val), rs2039117796, gnomAD 14-50587907-C-T, CADD 7.57
- L38L (p.Leu38Leu), rs1566722936, gnomAD 14-50587910-C-T, CADD 7.62
- I39M (p.Ile39Met), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- I39V (p.Ile39Val), rs756464141, ClinGen CA7180173, ClinVar RCV002028584, ClinVar RCV005493220, REVEL 0.04, CADD 11.20, Uncertain significance, not provided; Inborn genetic diseases; Hereditary spastic paraplegia 3A
- V40F (p.Val40Phe), rs2140201780, ClinGen CA389665438, ClinVar RCV001391389, Ensembl rs2140201780, AlphaMissense 0.70, MetaLR 0.14, Pathogenic, Hereditary spastic paraplegia 3A
- V40V (p.Val40Val), gnomAD 14-50587916-C-T, CADD 8.73
- K41K (p.Lys41Lys), rs2039117928, gnomAD 14-50587919-A-G, CADD 10.70
- D42V (p.Asp42Val), rs2140201784, ClinGen CA389665474, ClinVar RCV001366952, Ensembl rs2140201784, AlphaMissense 0.34, MetaLR 0.14, Uncertain significance, Hereditary spastic paraplegia 3A
- D42A (p.Asp42Ala), gnomAD 14-50587921-A-C, REVEL 0.25, CADD 22.70
- D42D (p.Asp42Asp), rs1330331510, gnomAD 14-50587922-T-C, CADD 5.42
- D43E (p.Asp43Glu), rs17850684, ClinGen CA342178, ClinVar RCV000020719, UniProt VAR 058963, AlphaMissense 0.20, MetaLR 0.23, not provided, Hereditary spastic paraplegia 3A
- D43N (p.Asp43Asn), rs1417905777, ClinGen CA389665481, ClinVar RCV000658147, gnomAD rs1417905777, REVEL 0.31, CADD 22.20, Uncertain significance, not provided
- D43V (p.Asp43Val), gnomAD rs1317806619, REVEL 0.63, CADD 26.60
- p.Asp43 His44del, rs771475691, gnomAD 14-50587920-GATGA, CADD 19.10
- D43D (p.Asp43Asp), rs17850684, gnomAD 14-50587925-C-T, AlphaMissense 0.20, MetaLR 0.23
- H44Q (p.His44Gln), rs2504484595, ClinGen CA389665507, ClinVar RCV002385903, Uncertain significance, Inborn genetic diseases
- S45A (p.Ser45Ala), rs2140201804, ClinGen CA389665515, ClinVar RCV002043441, Ensembl rs2140201804, AlphaMissense 0.08, MetaLR 0.33, Uncertain significance, Hereditary spastic paraplegia 3A
- S45F (p.Ser45Phe), gnomAD 14-50587930-C-T, REVEL 0.54, CADD 26.00
- F46S (p.Phe46Ser), ExAC rs778130435, TOPMed rs778130435, gnomAD rs778130435, REVEL 0.85, CADD 29.70
- F46F (p.Phe46Phe), gnomAD 14-50587934-T-C, CADD 13.60
- F46L (p.Phe46Leu), gnomAD 14-50587934-T-G, REVEL 0.54, CADD 25.70
- E47D (p.Glu47Asp), gnomAD rs2039118223, REVEL 0.30, CADD 19.70
- E47K (p.Glu47Lys), NCI-TCGA Cosmic COSV6329, cosmic curated COSV63296, Variant assessed as somatic; moderate impact.
- E47E (p.Glu47Glu), gnomAD 14-50587937-G-A, CADD 9.77
- L48* (p.Leu48Ter), gnomAD 14-50587939-T-A, CADD 36.00
- D49E (p.Asp49Glu), rs2039118339, ClinGen CA389665580, ClinVar RCV003287791, TOPMed rs2039118339, AlphaMissense 0.36, MetaLR 0.32, Uncertain significance, Inborn genetic diseases
- D49G (p.Asp49Gly), TOPMed rs1172905535, gnomAD rs1172905535, REVEL 0.86, CADD 28.20
- D49N (p.Asp49Asn), gnomAD rs2039118256, REVEL 0.28, CADD 22.90
- D49Y (p.Asp49Tyr), gnomAD 14-50587941-G-T, REVEL 0.74, CADD 28.20
- D49A (p.Asp49Ala), gnomAD 14-50587942-A-C, REVEL 0.87, CADD 27.30
- E50K (p.Glu50Lys), gnomAD 14-50587944-G-A, REVEL 0.41, CADD 25.20
- E50D (p.Glu50Asp), rs755879849, gnomAD 14-50587944-GAAAC, CADD 29.20
- T51N (p.Thr51Asn), NCI-TCGA Cosmic COSV6329, cosmic curated COSV63297, Variant assessed as somatic; moderate impact.
- T51I (p.Thr51Ile), gnomAD 14-50587948-C-T, REVEL 0.17, CADD 19.30
- T51S (p.Thr51Ser), gnomAD 14-50587948-C-G, REVEL 0.10, CADD 13.60
- A52E (p.Ala52Glu), Ensembl rs1469122610
- A52S (p.Ala52Ser), Ensembl rs2039118424
- A52A (p.Ala52Ala), gnomAD 14-50587952-A-G, CADD 2.81
- R55Q (p.Arg55Gln), rs564832738, ClinGen CA7180177, cosmic curated COSV63295, ClinVar RCV000533437, REVEL 0.10, CADD 22.10, Uncertain significance, not provided; Hereditary spastic paraplegia 3A; Inborn genetic diseases
- R55W (p.Arg55Trp), rs149901427, ClinGen CA7180176, cosmic curated COSV10061, ClinVar RCV000702118, REVEL 0.32, CADD 26.00, Uncertain significance, Hereditary spastic paraplegia 3A; not provided; Inborn genetic diseases
- R55R (p.Arg55Arg), rs149901427, gnomAD 14-50587959-C-A, CADD 11.50
- I56T (p.Ile56Thr), ExAC rs778699311, TOPMed rs778699311, gnomAD rs778699311, REVEL 0.86, CADD 26.70, Uncertain significance, Hereditary spastic paraplegia 3A
- I56I (p.Ile56Ile), gnomAD 14-50587964-C-A, CADD 10.10
- L57F (p.Leu57Phe), rs2039118655, ClinGen CA389665678, ClinVar RCV001195765, Ensembl rs2039118655, REVEL 0.75, CADD 25.30, Uncertain significance, Neuropathy, hereditary sensory, type 1D
- L58F (p.Leu58Phe), gnomAD rs1351467376, REVEL 0.54, CADD 25.10
- L58H (p.Leu58His), gnomAD rs1204026974, REVEL 0.73, CADD 27.40
- L58I (p.Leu58Ile), gnomAD rs1351467376
- L58del (p.Leu58del), gnomAD 14-50587964-CCTT-, CADD 19.40
- S59A (p.Ser59Ala), TOPMed rs955736784, REVEL 0.09, CADD 20.60
- S59L (p.Ser59Leu), rs1278783412, ClinGen CA389665703, NCI-TCGA Cosmic COSV6329, cosmic curated COSV63296, REVEL 0.14, CADD 23.30, Uncertain significance, Hereditary spastic paraplegia 3A; Inborn genetic diseases
- S59S (p.Ser59Ser), rs201580688, gnomAD 14-50587973-G-T, CADD 0.74
- E60A (p.Glu60Ala), rs2504484865, ClinGen CA389665713, ClinVar RCV003056433, Uncertain significance, Hereditary spastic paraplegia 3A
- E60Q (p.Glu60Gln), rs2140201888, ClinGen CA389665711, ClinVar RCV001950632, Ensembl rs2140201888, AlphaMissense 0.18, MetaLR 0.24, Uncertain significance, Hereditary spastic paraplegia 3A
- A61V (p.Ala61Val), rs1207501733, ClinGen CA389665730, ClinVar RCV002636166, ClinVar RCV005281206, REVEL 0.11, CADD 21.80, Uncertain significance, Hereditary spastic paraplegia 3A; Inborn genetic diseases
- A61A (p.Ala61Ala), rs771689808, gnomAD 14-50587979-T-C, CADD 11.40
- V62A (p.Val62Ala), gnomAD rs2039118968, REVEL 0.54, CADD 26.80
- V62L (p.Val62Leu), gnomAD 14-50587980-G-C, REVEL 0.34, CADD 23.20
- R63R (p.Arg63Arg), gnomAD 14-50587985-A-G, CADD 10.70
- D64D (p.Asp64Asp), rs974359414, gnomAD 14-50587988-C-T, CADD 10.60
- K65N (p.Lys65Asn), NCI-TCGA Cosmic COSV1006, cosmic curated COSV10061, REVEL 0.35, CADD 22.10, Variant assessed as somatic; moderate impact.
- E66K (p.Glu66Lys), rs200314808, ClinGen CA389665780, ClinVar RCV001341383, ESP rs200314808, REVEL 0.23, CADD 21.10, Uncertain significance, Hereditary spastic paraplegia 3A
- E66Q (p.Glu66Gln), rs200314808, ClinGen CA129352, ClinVar RCV000023543, ClinVar RCV000236565, REVEL 0.10, CADD 22.30, Conflicting interpretations, Inborn genetic diseases; Hereditary spastic paraplegia 3A; not provided
- E66E (p.Glu66Glu), rs1260793822, gnomAD 14-50587994-G-A, CADD 6.79
- V67A (p.Val67Ala), rs768342546, ClinGen CA7180182, ClinVar RCV001398337, ExAC rs768342546, REVEL 0.76, CADD 27.10, Likely benign, Hereditary spastic paraplegia 3A
- V67F (p.Val67Phe), ExAC rs746927118, gnomAD rs746927118, REVEL 0.88, CADD 26.30
- V67I (p.Val67Ile), gnomAD 14-50587995-G-A, REVEL 0.41, CADD 22.40
- V68G (p.Val68Gly), NCI-TCGA Cosmic COSV6329, cosmic curated COSV63297, Variant assessed as somatic; moderate impact.
- V68V (p.Val68Val), rs776429880, gnomAD 14-50588000-T-C, CADD 4.21
- A69S (p.Ala69Ser), TOPMed rs2039119322, Uncertain significance, Inborn genetic diseases
- A69V (p.Ala69Val), rs2140201934, ClinGen CA389665826, ClinVar RCV001364369, Ensembl rs2140201934, REVEL 0.20, CADD 18.40, Uncertain significance, Hereditary spastic paraplegia 3A
- A69T (p.Ala69Thr), gnomAD 14-50588001-G-A, REVEL 0.34, CADD 24.80
- V70E (p.Val70Glu), rs2140201941, ClinGen CA389665835, ClinVar RCV001754485, Ensembl rs2140201941, AlphaMissense 1.00, MetaLR 0.60, Uncertain significance, not provided
- V70I (p.Val70Ile), ExAC rs761583539, TOPMed rs761583539, gnomAD rs761583539, REVEL 0.07, CADD 21.60, Uncertain significance
- V70L (p.Val70Leu), rs761583539, ClinGen CA7180184, ClinVar RCV003219067, ExAC rs761583539, REVEL 0.26, CADD 22.30, Uncertain significance, not provided
- V70V (p.Val70Val), gnomAD 14-50588006-A-G, CADD 4.64
- S71C (p.Ser71Cys), gnomAD 14-50588008-C-G, REVEL 0.68, CADD 26.10
- V72I (p.Val72Ile), ExAC rs766627863, gnomAD rs766627863, REVEL 0.24, CADD 25.90
- A73T (p.Ala73Thr), gnomAD rs1416275162, REVEL 0.59, CADD 27.90
- A73V (p.Ala73Val), rs951568761, ClinGen CA260772439, ClinVar RCV003397779, Ensembl rs951568761, AlphaMissense 0.95, MetaLR 0.28, Uncertain significance, ATL1-related disorder
- G74G (p.Gly74Gly), gnomAD 14-50588018-A-G, CADD 10.90
- A75T (p.Ala75Thr), 1000Genomes rs182963739, ExAC rs182963739, gnomAD rs182963739, REVEL 0.48, CADD 25.00
- A75P (p.Ala75Pro), gnomAD 14-50588019-G-C, REVEL 0.47, CADD 27.60
- F76Y (p.Phe76Tyr), cosmic curated COSV63295, Ensembl rs2039119643
- F76L (p.Phe76Leu), gnomAD 14-50588024-T-G, REVEL 0.67, CADD 23.50
- R77R (p.Arg77Arg), gnomAD 14-50588027-A-G, CADD 8.66
- K78N (p.Lys78Asn), gnomAD 14-50588030-A-T, REVEL 0.47, CADD 26.50
- G79R (p.Gly79Arg), gnomAD 14-50588031-G-A, REVEL 0.96, CADD 29.10
- S81* (p.Ser81Ter), Ensembl rs2039119725
- S81L (p.Ser81Leu), NCI-TCGA Cosmic COSV1006, cosmic curated COSV10061, Variant assessed as somatic; moderate impact.
- S81S (p.Ser81Ser), gnomAD 14-50588039-A-G, CADD 4.32
- F82L (p.Phe82Leu), TOPMed rs1350735934, gnomAD rs1350735934, NCI-TCGA TCGA novel, REVEL 0.80, CADD 22.90, Variant assessed as somatic; moderate impact.
- L83L (p.Leu83Leu), rs2039119808, gnomAD 14-50588045-G-C, CADD 7.18
- D85G (p.Asp85Gly), rs2140201974, ClinGen CA389666020, ClinVar RCV001987055, Ensembl rs2140201974, AlphaMissense 0.94, MetaLR 0.68, Uncertain significance, Hereditary spastic paraplegia 3A
- D85A (p.Asp85Ala), gnomAD 14-50588050-A-C, REVEL 0.70, CADD 28.20
- F86L (p.Phe86Leu), TOPMed rs2039119846, REVEL 0.51, CADD 28.20
- M87I (p.Met87Ile), rs759633651, ClinGen CA7180187, ClinVar RCV002929060, ClinVar RCV003274099, REVEL 0.30, CADD 23.70, Uncertain significance, Hereditary spastic paraplegia 3A; Inborn genetic diseases
- M87L (p.Met87Leu), gnomAD 14-50588055-A-T, REVEL 0.17, CADD 22.30
- L88W (p.Leu88Trp), gnomAD 14-50588059-T-G, REVEL 0.83, CADD 28.90
- R89R (p.Arg89Arg), gnomAD 14-50588063-A-G, CADD 14.90
- Y90H (p.Tyr90His), rs767543400, ClinGen CA7180188, ClinVar RCV002659245, ClinVar RCV003151902, REVEL 0.82, CADD 28.70, Uncertain significance, Hereditary spastic paraplegia 3A; not provided
- Y90* (p.Tyr90Ter), gnomAD 14-50588066-C-A, CADD 35.00
- M91I (p.Met91Ile), ExAC rs753147363, gnomAD rs753147363, Uncertain significance, not provided
- M91L (p.Met91Leu), rs985606716, ClinGen CA389666061, ClinVar RCV002842683, REVEL 0.22, AlphaMissense 0.32, Uncertain significance, Hereditary spastic paraplegia 3A
- M91V (p.Met91Val), rs985606716, ClinGen CA260772463, ClinVar RCV003842439, TOPMed rs985606716, AlphaMissense 0.32, MetaLR 0.37, Uncertain significance, Hereditary spastic paraplegia 3A
Public ATL1 analysis runs
- ATL1 analysis run — ATL1 (761 variants) — completed 2026-08-22